

N-((1R)-1-{4-[4-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-4-hydroxybutyl)phenyl]-1-methylimidazol-2-yl}-2-hydroxyethyl)acetamide;  
N-((1R)-1-{4-[4-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-4-hydroxybutyl)phenyl]-1-methylimidazol-2-yl}-2-hydroxyethyl)methoxycarboxamide;  
(3R)-3-{4-[4-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-4-hydroxybutyl)phenyl]-1-methylimidazol-2-yl}-3-(acetylamino)propanoic acid;  
N-((1R)-1-{4-[4-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-4-hydroxybutyl)phenyl]-1-methylimidazol-2-yl}ethyl)isoxazol-5-ylcarboxamide;  
N-((1R)-1-{4-[4-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-4-hydroxybutyl)phenyl]-1-methylimidazol-2-yl}ethyl)-2-methoxyacetamide;  
N-((1R)-1-{4-[4-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-4-hydroxybutyl)phenyl]-1-methylimidazol-2-yl}ethyl)-2-furylcarboxamide;  
N-(2-{{4-((1R)-2,2,2-trifluoro-isopropoxy)-3-chlorophenyl}carbonylamino}(2S)-3-{4-[1-ethyl-2-(1-hydroxy-isopropyl)imidazol-4-yl]phenyl}propyl)-2-(dimethylamino)acetamide;  
N-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-3-{4-[1-ethyl-2-(1-hydroxy-isopropyl)imidazol-4-yl]phenyl}propyl)-2-(dimethylamino)acetamide;  
N-(2-{{4-((1R)-2,2,2-trifluoro-isopropoxy)-3-chlorophenyl}carbonylamino}(2S)-3-{4-[1-ethyl-2-(1-hydroxy-isopropyl)imidazol-4-yl]phenyl}propyl)-2-azetidinylacetamide;  
N-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-3-{4-[1-ethyl-2-(1-hydroxy-isopropyl)imidazol-4-yl]phenyl}propyl)-2-azetidinylacetamide;

N-(2-{{4-((1R)-2,2,2-trifluoro-isopropoxy)-3-chlorophenyl}carbonylamino}(2S)-3-{4-[1-ethyl-2-(1-hydroxy-isopropyl)imidazol-4-yl]phenyl}propyl)-2-morpholin-4-ylacetamide; and

N-((2S)-2-[[3-chloro-4-(methylethoxy)phenyl]carbonylamino]-3-{4-[1-ethyl-2-(1-hydroxy-isopropyl)imidazol-4-yl]phenyl}propyl)-2-morpholin-4-ylacetamide.

**39.** A composition comprising a pharmaceutical excipient and at least one chemical entity of claim 1.

**40.** A composition according to claim 37, wherein said composition further comprises a chemotherapeutic agent other than a compound of Formula I.

**41.** A composition according to claim 38, wherein said composition further comprises a taxane, a vinca alkaloid, or a topoisomerase I inhibitor.

**42.** A method of modulating CENP-E kinesin activity which comprises contacting said kinesin with an effective amount of at least one chemical entity of claim 1.

**43.** A method of inhibiting CENP-E which comprises contacting said kinesin with an effective amount of at least one chemical entity of claim 1.

**44.** A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof at least one chemical entity of claim 1.

**45.** A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof a composition according to claim 37.

**46.** A method according to claim 42 wherein said disease is selected from the group consisting of cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, and inflammation.

\* \* \* \* \*